Scinai Immunotherapeutics (SCNI) Capital Expenditures (2018 - 2024)

Scinai Immunotherapeutics has disclosed Capital Expenditures across 7 years of filings, most recently posting $24000.0 for Q4 2024.

• Capital Expenditures for Q4 2024 came in at $24000.0, down 97.69% year-over-year; the trailing twelve-month figure through Dec 2024 was $12000.0 (down 98.12% YoY), and the FY2025 annual result was $24000.0, up 100.0% from the prior year.
• Capital Expenditures came in at $24000.0 for Q4 2024 at Scinai Immunotherapeutics, up from -$4000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.4 million in Q4 2022 to a low of -$3.3 million in Q3 2020.
• The 5-year median for Capital Expenditures is -$6000.0 (2023), against an average of -$118368.4.
• Peak annual rise in Capital Expenditures reached 7542.86% in 2022, while the deepest fall reached 1900.0% in 2022.
• Scinai Immunotherapeutics' Capital Expenditures stood at -$97000.0 in 2020, then jumped by 285.57% to $180000.0 in 2021, then soared by 678.89% to $1.4 million in 2022, then declined by 25.82% to $1.0 million in 2023, then sank by 97.69% to $24000.0 in 2024.
• The last three Capital Expenditures figures came in at $24000.0 (Q4 2024), -$4000.0 (Q3 2024), and -$6000.0 (Q2 2024), per Business Quant data.